Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 5/20 | 0.62 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.58 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.58 |
| ▸ | CCNE2 | O96020 | 4/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.52 |
| ▸ | CDK2 | P24941 | 4/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7672785 | 0.80 | PDGFRA (0.48) | CTSLCCNE1CDK2MAPT | |
| SCHEMBL7674300 | 0.80 | CTSL (0.50) | CTSLTLR9TLR7CCNE2CCNE1 | |
| SCHEMBL7673595 | 0.78 | KDM4E (0.45) | CTSLCCNE1CDK2TDP1MAPT | |
| SCHEMBL7668634 | 0.76 | CCNE1 (0.54) | CTSLCCNE2CCNE1CDK2TMIGD3 | |
| SCHEMBL7661594 | 0.76 | CDK2 (0.43) | CTSLCCNE1CDK2 | |
| SCHEMBL6944109 | 0.74 | CCNE2 (0.76) | CTSLCCNE2CCNE1CDK2TDP1 | |
| SCHEMBL7667683 | 0.74 | CCNE1 (0.55) | CTSLCCNE1CDK2 | |
| SCHEMBL5462682 | 0.74 | CTSL (0.59) | CTSLTLR9TLR7CCNE2CCNE1 | |
| SCHEMBL22401485 | 0.74 | TLR9 (1.00) | TLR9TLR7 | |
| SCHEMBL7666120 | 0.73 | PDGFRA (0.49) | CTSLCCNE1CDK2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6414147-B1 | DIAGNOSIS AND TREATMENT OF ANXIETY, DEPRESSION, SLEEP AND SEIZURE DISORDERS, DOWN'S SYNDROME, OVERDOSE WITH BENZODIAZEPINE DRUGS, AND FOR ENHANCEMENT OF MEMORY | NEUROGEN CORPORATION | 2002-07-02 | — | — | US | claimed |
| US-6414147-B1 | DIAGNOSIS AND TREATMENT OF ANXIETY, DEPRESSION, SLEEP AND SEIZURE DISORDERS, DOWN'S SYNDROME, OVERDOSE WITH BENZODIAZEPINE DRUGS, AND FOR ENHANCEMENT OF MEMORY | NEUROGEN CORPORATION | 2002-07-02 | — | — | US | disclosed |